{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"St John's Wort\" outputclass=\"int-drug\">St John's Wort</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  St John's Wort  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's Wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"afatinib\" outputclass=\"int-drug\">afatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  afatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Afatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"aflibercept\" outputclass=\"int-drug\">aflibercept</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  aflibercept  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aflibercept</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"alcohol (beverage)\" outputclass=\"int-drug\">Alcohol (beverage)</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">a disulfiram-like reaction when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Alcohol (beverage)   potentially   causes   a disulfiram-like reaction when given with   procarbazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alcohol (beverage)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"alemtuzumab\" outputclass=\"int-drug\">alemtuzumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  alemtuzumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alemtuzumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"almotriptan\" outputclass=\"int-drug\">almotriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  almotriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Almotriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"amsacrine\" outputclass=\"int-drug\">amsacrine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  amsacrine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amsacrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"anakinra\" outputclass=\"int-drug\">anakinra</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  anakinra  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anakinra</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  arsenic trioxide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"asparaginase\" outputclass=\"int-drug\">asparaginase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  asparaginase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asparaginase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  axitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"azacitidine\" outputclass=\"int-drug\">azacitidine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  azacitidine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azacitidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"azathioprine\" outputclass=\"int-drug\">azathioprine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  azathioprine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azathioprine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"Bacillus Calmette-Guérin vaccine\" outputclass=\"int-drug\">Bacillus Calmette-Guérin vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bacillus Calmette-Guérin vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   procarbazine .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacillus Calmette-Guérin vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"balsalazide\" outputclass=\"int-drug\">balsalazide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  balsalazide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Balsalazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"belimumab\" outputclass=\"int-drug\">belimumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  belimumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Belimumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"bendamustine\" outputclass=\"int-drug\">bendamustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  bendamustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendamustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  bevacizumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"bleomycin\" outputclass=\"int-drug\">bleomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  bleomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bleomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"blinatumomab\" outputclass=\"int-drug\">blinatumomab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  blinatumomab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Blinatumomab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  bortezomib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bortezomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  bosutinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-drug\">brentuximab vedotin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  brentuximab vedotin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brentuximab vedotin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"bupropion\" outputclass=\"int-drug\">bupropion</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  bupropion  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupropion</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"buspirone\" outputclass=\"int-drug\">buspirone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  buspirone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buspirone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"busulfan\" outputclass=\"int-drug\">busulfan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  busulfan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Busulfan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">cabazitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  cabazitaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabazitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  cabozantinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"canakinumab\" outputclass=\"int-drug\">canakinumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  canakinumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canakinumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757490",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757490_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"capecitabine\" outputclass=\"int-drug\">capecitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  capecitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capecitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757491",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757491_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypersensitivity reactions when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   increase   the risk of hypersensitivity reactions when given with   procarbazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757492",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757492_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"carbimazole\" outputclass=\"int-drug\">carbimazole</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  carbimazole  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbimazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757493",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757493_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  carboplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757494",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757494_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"carfilzomib\" outputclass=\"int-drug\">carfilzomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  carfilzomib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carfilzomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757495",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757495_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"carmustine\" outputclass=\"int-drug\">carmustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  carmustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carmustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757496",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757496_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  ceritinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757497",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757497_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"cetuximab\" outputclass=\"int-drug\">cetuximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  cetuximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cetuximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757498",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757498_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"chlorambucil\" outputclass=\"int-drug\">chlorambucil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  chlorambucil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorambucil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757499",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757499_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  cisplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757500",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757500_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  citalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757501",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757501_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"cladribine\" outputclass=\"int-drug\">cladribine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  cladribine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cladribine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757502",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757502_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"clofarabine\" outputclass=\"int-drug\">clofarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  clofarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clofarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757503",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757503_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  clomipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757504",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757504_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  clozapine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clozapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757505",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757505_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"co-trimoxazole\" outputclass=\"int-drug\">co-trimoxazole</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  co-trimoxazole  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Co-trimoxazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757506",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757506_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"crisantaspase\" outputclass=\"int-drug\">crisantaspase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  crisantaspase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crisantaspase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757507",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757507_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">crizotinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  crizotinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757508",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757508_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"cyclophosphamide\" outputclass=\"int-drug\">cyclophosphamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  cyclophosphamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclophosphamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757509",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757509_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"cytarabine\" outputclass=\"int-drug\">cytarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  cytarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cytarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757510",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757510_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"dabrafenib\" outputclass=\"int-drug\">dabrafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  dabrafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabrafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757511",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757511_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"dacarbazine\" outputclass=\"int-drug\">dacarbazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  dacarbazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dacarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757512",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757512_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"dactinomycin\" outputclass=\"int-drug\">dactinomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  dactinomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dactinomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757513",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757513_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  dapoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757514",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757514_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  dasatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757515",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757515_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"daunorubicin\" outputclass=\"int-drug\">daunorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  daunorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daunorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757516",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757516_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"decitabine\" outputclass=\"int-drug\">decitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  decitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Decitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"deferiprone\" outputclass=\"int-drug\">deferiprone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  deferiprone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferiprone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"dexamfetamine\" outputclass=\"int-drug\">dexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  dexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"docetaxel\" outputclass=\"int-drug\">docetaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  docetaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Docetaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"doxorubicin\" outputclass=\"int-drug\">doxorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  doxorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  duloxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"eletriptan\" outputclass=\"int-drug\">eletriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  eletriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eletriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"epirubicin\" outputclass=\"int-drug\">epirubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  epirubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epirubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  eribulin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  escitalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"estramustine\" outputclass=\"int-drug\">estramustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  estramustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Estramustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"ethosuximide\" outputclass=\"int-drug\">ethosuximide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  ethosuximide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ethosuximide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"etoposide\" outputclass=\"int-drug\">etoposide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  etoposide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoposide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"everolimus\" outputclass=\"int-drug\">everolimus</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  everolimus  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Everolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  fentanyl  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"fludarabine\" outputclass=\"int-drug\">fludarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  fludarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757532",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757532_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"fluorouracil\" outputclass=\"int-drug\">fluorouracil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  fluorouracil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluorouracil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757533",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757533_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  fluoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  fluvoxamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypersensitivity when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   increase   the risk of hypersensitivity when given with   procarbazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757536",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757536_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"frovatriptan\" outputclass=\"int-drug\">frovatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  frovatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Frovatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757537",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757537_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  ganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757538",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757538_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"gefitinib\" outputclass=\"int-drug\">gefitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  gefitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gefitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757539",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757539_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"gemcitabine\" outputclass=\"int-drug\">gemcitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  gemcitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemcitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757540",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757540_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"granisetron\" outputclass=\"int-drug\">granisetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  granisetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757541",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757541_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"hydroxycarbamide\" outputclass=\"int-drug\">hydroxycarbamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  hydroxycarbamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxycarbamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757542",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757542_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  ibrutinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757543",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757543_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"idarubicin\" outputclass=\"int-drug\">idarubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  idarubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idarubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757544",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757544_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">idelalisib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  idelalisib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757545",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757545_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"ifosfamide\" outputclass=\"int-drug\">ifosfamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  ifosfamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ifosfamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757546",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757546_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  imatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757547",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757547_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  imipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757548",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757548_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"influenza vaccine (live)\" outputclass=\"int-drug\">Influenza vaccine (live)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Influenza vaccine (live)   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   procarbazine .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Influenza vaccine (live)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757549",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757549_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"interferon alfa\" outputclass=\"int-drug\">interferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  interferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Interferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757550",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757550_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"interferon beta\" outputclass=\"int-drug\">interferon beta</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  interferon beta  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Interferon beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757551",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757551_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"irinotecan\" outputclass=\"int-drug\">irinotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  irinotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irinotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757552",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757552_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  isocarboxazid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757553",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757553_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">leflunomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  leflunomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757554",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757554_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"lenalidomide\" outputclass=\"int-drug\">lenalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  lenalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757555",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757555_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  linezolid  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757555_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  procarbazine  and  linezolid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linezolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757556",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757556_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"lisdexamfetamine\" outputclass=\"int-drug\">lisdexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  lisdexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisdexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757557",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757557_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  lithium  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757558",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757558_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"lomustine\" outputclass=\"int-drug\">lomustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  lomustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757559",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757559_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"measles, mumps and rubella vaccine, live\" outputclass=\"int-drug\">Measles, mumps and rubella vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Measles, mumps and rubella vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   procarbazine .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Measles, mumps and rubella vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757560",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757560_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"melphalan\" outputclass=\"int-drug\">melphalan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  melphalan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Melphalan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757561",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757561_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"mercaptopurine\" outputclass=\"int-drug\">mercaptopurine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  mercaptopurine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mercaptopurine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757562",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757562_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  methadone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757563",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757563_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  methotrexate  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757564",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757564_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"methylthioninium chloride\" outputclass=\"int-drug\">methylthioninium chloride</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  methylthioninium chloride  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylthioninium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757565",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757565_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"mianserin\" outputclass=\"int-drug\">mianserin</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  mianserin  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mianserin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757566",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757566_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  mirtazapine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirtazapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757567",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757567_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"mitomycin\" outputclass=\"int-drug\">mitomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  mitomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757568",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757568_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"mitotane\" outputclass=\"int-drug\">mitotane</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  mitotane  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757569",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757569_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"mitoxantrone\" outputclass=\"int-drug\">mitoxantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  mitoxantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitoxantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757570",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757570_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"moclobemide\" outputclass=\"int-drug\">moclobemide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  moclobemide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moclobemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757571",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757571_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"mycophenolate\" outputclass=\"int-drug\">mycophenolate</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  mycophenolate  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mycophenolate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757572",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757572_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"naratriptan\" outputclass=\"int-drug\">naratriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  naratriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naratriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757573",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757573_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"nelarabine\" outputclass=\"int-drug\">nelarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  nelarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nelarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757574",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757574_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  nilotinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757575",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757575_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"nivolumab\" outputclass=\"int-drug\">nivolumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  nivolumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nivolumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757576",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757576_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"obinutuzumab\" outputclass=\"int-drug\">obinutuzumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  obinutuzumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Obinutuzumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757577",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757577_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"ofatumumab\" outputclass=\"int-drug\">ofatumumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  ofatumumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ofatumumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757578",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757578_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  olanzapine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olanzapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757579",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757579_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"olaparib\" outputclass=\"int-drug\">olaparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  olaparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757580",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757580_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"olsalazine\" outputclass=\"int-drug\">olsalazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  olsalazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olsalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757581",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757581_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  ondansetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757582",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757582_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  oxaliplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757583",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757583_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  paclitaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paclitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757584",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757584_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">palonosetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  palonosetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757585",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757585_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"panitumumab\" outputclass=\"int-drug\">panitumumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  panitumumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panitumumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757586",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757586_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  panobinostat  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757587",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757587_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  paroxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757588",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757588_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  pazopanib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757589",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757589_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"pegaspargase\" outputclass=\"int-drug\">pegaspargase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  pegaspargase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pegaspargase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757590",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757590_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"peginterferon alfa\" outputclass=\"int-drug\">peginterferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  peginterferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Peginterferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757591",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757591_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"peginterferon beta-1a\" outputclass=\"int-drug\">peginterferon beta-1a</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  peginterferon beta-1a  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Peginterferon beta-1a</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757592",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757592_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  pemetrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757593",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757593_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  pentamidine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757594",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757594_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  pentazocine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentazocine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757595",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757595_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"pentostatin\" outputclass=\"int-drug\">pentostatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  pentostatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentostatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757596",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757596_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  pethidine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757597",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757597_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  phenelzine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757598",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757598_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypersensitivity reactions when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   increase   the risk of hypersensitivity reactions when given with   procarbazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757599",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757599_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypersensitivity reactions when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   increase   the risk of hypersensitivity reactions when given with   procarbazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757600",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757600_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"pixantrone\" outputclass=\"int-drug\">pixantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  pixantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pixantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757601",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757601_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"pomalidomide\" outputclass=\"int-drug\">pomalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  pomalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pomalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757602",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757602_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"primaquine\" outputclass=\"int-drug\">primaquine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  primaquine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primaquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757603",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757603_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypersensitivity reactions when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   increase   the risk of hypersensitivity reactions when given with   procarbazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757604",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757604_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"propylthiouracil\" outputclass=\"int-drug\">propylthiouracil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  propylthiouracil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propylthiouracil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757605",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757605_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"pyrimethamine\" outputclass=\"int-drug\">pyrimethamine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  pyrimethamine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pyrimethamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757606",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757606_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"raltitrexed\" outputclass=\"int-drug\">raltitrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  raltitrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Raltitrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757607",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757607_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"ramucirumab\" outputclass=\"int-drug\">ramucirumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  ramucirumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramucirumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757608",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757608_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">rasagiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  rasagiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rasagiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757609",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757609_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  regorafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757610",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757610_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"rituximab\" outputclass=\"int-drug\">rituximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  rituximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rituximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757611",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757611_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"rizatriptan\" outputclass=\"int-drug\">rizatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  rizatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rizatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757612",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757612_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rotavirus vaccine\" outputclass=\"int-drug\">Rotavirus vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rotavirus vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   procarbazine .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rotavirus vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757613",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757613_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  ruxolitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757614",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757614_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"safinamide\" outputclass=\"int-drug\">safinamide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  safinamide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Safinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757615",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757615_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  selegiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757616",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757616_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  sertraline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757617",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757617_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"siltuximab\" outputclass=\"int-drug\">siltuximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  siltuximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Siltuximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757618",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757618_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  sorafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757619",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757619_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"sulfadiazine\" outputclass=\"int-drug\">sulfadiazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  sulfadiazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfadiazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757620",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757620_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"sulfasalazine\" outputclass=\"int-drug\">sulfasalazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  sulfasalazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfasalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757621",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757621_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"sumatriptan\" outputclass=\"int-drug\">sumatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  sumatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sumatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757622",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757622_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  sunitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757623",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757623_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">tapentadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  tapentadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tapentadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757624",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757624_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"temozolomide\" outputclass=\"int-drug\">temozolomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  temozolomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temozolomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757625",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757625_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"temsirolimus\" outputclass=\"int-drug\">temsirolimus</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  temsirolimus  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temsirolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757626",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757626_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  thalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757627",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757627_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"thiotepa\" outputclass=\"int-drug\">thiotepa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  thiotepa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiotepa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757628",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757628_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"tioguanine\" outputclass=\"int-drug\">tioguanine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  tioguanine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tioguanine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757629",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757629_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"topotecan\" outputclass=\"int-drug\">topotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  topotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757630",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757630_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"trabectedin\" outputclass=\"int-drug\">trabectedin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  trabectedin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trabectedin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757631",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757631_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  tramadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tramadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757632",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757632_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  tranylcypromine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757633",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757633_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  trastuzumab emtansine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757634",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757634_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  trazodone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757635",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757635_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"treosulfan\" outputclass=\"int-drug\">treosulfan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  treosulfan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treosulfan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757636",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757636_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"tryptophan\" outputclass=\"int-drug\">tryptophan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  tryptophan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tryptophan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757637",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757637_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"typhoid vaccine, oral\" outputclass=\"int-drug\">Typhoid vaccine, oral</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Typhoid vaccine, oral   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   procarbazine .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Typhoid vaccine, oral</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757638",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757638_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  valganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757639",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757639_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"varicella-zoster vaccine\" outputclass=\"int-drug\">Varicella-zoster vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Varicella-zoster vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   procarbazine .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Varicella-zoster vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757640",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757640_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  venlafaxine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757641",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757641_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  vinblastine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinblastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757642",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757642_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  vincristine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757643",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757643_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  vindesine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vindesine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757644",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757644_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  vinflunine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757645",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757645_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  vinorelbine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinorelbine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757646",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757646_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"vismodegib\" outputclass=\"int-drug\">vismodegib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  vismodegib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vismodegib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757647",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757647_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  vortioxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757648",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757648_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"yellow fever vaccine, live\" outputclass=\"int-drug\">Yellow fever vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Yellow fever vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   procarbazine .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Yellow fever vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757649",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757649_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">zidovudine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  zidovudine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zidovudine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757650",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2#bnf_i1557280757650_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"procarbazine\" outputclass=\"int-heading-drug\">procarbazine</ph> and <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\">zolmitriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  procarbazine  and  zolmitriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolmitriptan</title>"
					}
				}
			],
			"hasSearchLabel": " Procarbazine  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/procarbazine-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Procarbazine </title>"
			},
			"rdfs:label": "procarbazine"
		}
	]
}